- Trials with a EudraCT protocol (4)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
4 result(s) found for: CA15-3.
Displaying page 1 of 1.
EudraCT Number: 2006-004332-79 | Sponsor Protocol Number: GINECO-BR105 | Start Date*: 2007-07-10 |
Sponsor Name:ARCAGY | ||
Full Title: "Essai multicentrique de phase II randomisé évaluant la tolérance et l'efficacité du tamoxifène seul versus association Tamoxifène-RAD001 (Everolimus), chez les patientes atteintes de cancer du sei... | ||
Medical condition: metastatic breast cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: FR (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-016338-29 | Sponsor Protocol Number: GINECO-BR107 | Start Date*: 2009-11-16 |
Sponsor Name:ARCAGY | ||
Full Title: Essai randomisé multicentrique de phase III comparant la poursuite du traitement d’entretien par l’association bevacizumab + taxane versus remplacement par bevacizumab + exemestane chez des patient... | ||
Medical condition: Metastatic breast cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: FR (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-000260-14 | Sponsor Protocol Number: UC-0140/1901 | Start Date*: 2020-01-30 | ||||||||||||||||
Sponsor Name:UNICANCER | ||||||||||||||||||
Full Title: Open-label, randomized, multicenter, phase III study, comparing standard chemotherapy to standard combination of endocrine therapy with Abemaciclib as initial Metastatic treatment among patients wi... | ||||||||||||||||||
Medical condition: Untreated metastatic Estrogen Receptor positive (ER+), Human Epidermal Growth Factor Receptor-2 negative (HER2-) breast cancer with visceral involvement. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: FR (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-004294-21 | Sponsor Protocol Number: FBT-IVREXBC 02 | Start Date*: 2006-03-14 |
Sponsor Name:Fresenius Biotech GmbH | ||
Full Title: Phase II study of the trifunctional anti-HER-2/neu x anti-CD3 antibody ertumaxomab for hormone therapy refractory patients with HER-2/neu 1+ or 2+ expressing advanced or metastatic breast cancer | ||
Medical condition: Hormone therapy refractory advanced or metastatic breast cancer tumors (stage IIIb or IV) which are known to express HER-2/neu (1+ or 2+) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: BE (Completed) ES (Completed) IT (Prematurely Ended) AT (Prematurely Ended) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
